Who
BVF PARTNERS L P/IL
Director and Other role
Company insider
Files Form 4 as: Director and Other, Immunic; Director and 10% owner and Other, XOMA Royalty; Director and Other, Kymera Therapeutics; Director and Other, Olema Pharmaceuticals; Director and 10% owner, MoonLake Immunotherapeutics; 10% owner, Repare Therapeutics; Director and 10% owner and Other, Cti Biopharma; Other, IDEAYA Biosciences.
In numbers
- Trades disclosed
- 225
- Buys
- 58
- Sells
- 7
- Bought
- $30.1M
- Sold
- $246.7M
- Companies
- 25
- Companies where not an officer
- 25
- First trade
- 6 Nov 2007
- Last trade
- 16 Sep 2026
- Last filed
- 18 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Sep 2026filed 18 Sep 2026 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,370 at $0.00 | filing |
| 14 Jul 2026filed 16 Jul 2026 | XOMA RoyaltyBiotechnology | SEC FORM 4 Code U | —3,635,758 | filing |
| 14 Jul 2026filed 16 Jul 2026 | XOMA RoyaltyBiotechnology | SEC FORM 4 Code U | —2,773,545 | filing |
| 14 Jul 2026filed 16 Jul 2026 | XOMA RoyaltyBiotechnology | SEC FORM 4 Code U | —412,000 | filing |
| 14 Jul 2026filed 16 Jul 2026 | XOMA RoyaltyBiotechnology | SEC FORM 4 Code U | —772,000 | filing |
| 26 Jun 2026filed 26 Jun 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $89.2M837,914 at $106.50 | filing |
| 26 Jun 2026filed 26 Jun 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $66.8M627,597 at $106.50 | filing |
| 26 Jun 2026filed 26 Jun 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $12.1M113,289 at $106.50 | filing |
| 26 Jun 2026filed 26 Jun 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $5.5M51,858 at $106.50 | filing |
| 24 Jun 2026filed 25 Jun 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,068 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | OLMA Olema Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,500 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | MLTX MoonLake Immunotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,195 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | XOMA RoyaltyBiotechnology | SEC FORM 4 Code C | $9.3M2,313,000 at $4.03 | filing |
| 14 May 2026filed 18 May 2026 | XOMA RoyaltyBiotechnology | SEC FORM 4 Code C | $6.1M1,506,000 at $4.03 | filing |
| 14 May 2026filed 18 May 2026 | XOMA RoyaltyBiotechnology | SEC FORM 4 Code C | $1.7M412,000 at $4.03 | filing |
| 14 May 2026filed 18 May 2026 | XOMA Royaltyoption or derivative | SEC FORM 4 Code C | —2,313 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | XOMA Royaltyoption or derivative | SEC FORM 4 Code C | —1,506 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | XOMA Royaltyoption or derivative | SEC FORM 4 Code C | —412 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | XOMA Royaltyoption or derivative | SEC FORM 4 Code C | —772 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | XOMA RoyaltyBiotechnology | SEC FORM 4 Code C | $3.1M772,000 at $4.03 | filing |
News
Head to Head Survey: Kymera Therapeutics (NASDAQ:KYMR) versus ADC Therapeutics (NYSE:ADCT)KYMR · dailypolitical.com · 8 Oct 2026
0 headlines in the last 90 days name BVF PARTNERS L P/IL; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.